RIVERVEST NEWSLETTER

June 2026 Issue

RiverVest invites you to read our latest newsletter, featuring:

  • Portfolio Company Avalyn Pharma Completes Upsized $345 Million           IPO              
  • 2026 Annual Meeting Recap
  • Atalanta Therapeutics: Reaching the Unreachable in Huntington’s             Disease by Pascal Krotee, PhD
  • Portfolio News

RiverVest News features insights and updates on the Science, Strategy, and Innovation behind our investments. 

 

 Subscribe to our newsletter (delivered to your email inbox three times per year)

 

  Read Past Issues of RiverVest News  (Newsletter Archive)

About RiverVest

RiverVest Venture Partners is a leading venture capital firm building life science companies to address significant unmet needs of patients and deliver consistently strong returns to investors. With headquarters in St. Louis and offices in San Diego and Cleveland, RiverVest accesses forward-thinking research and clinical expertise at leading institutions across the country to found and fund biopharma and medical device companies.

Paragraph